United Therapeutics (UTHR) director exercises options, then sells 4,910 shares

Rhea-AI Filing Summary

United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of 101.8000. On the same date, he then sold 4,910 shares of common stock at a reported price per share of 489.0200. After these transactions, his directly owned common stock holdings were 12,670 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KURZWEIL RAY

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		4,910	A	$101.8	17,580	D
Common Stock	03/04/2026		S		4,910	D	$489.02	12,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$101.8	03/04/2026		M			4,910	06/21/2017	06/21/2026	Common Stock	4,910	$0.00	0.00	D

Explanation of Responses:

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Ray Kurzweil report for UNITED THERAPEUTICS (UTHR)?

Ray Kurzweil reported exercising options and selling shares of UNITED THERAPEUTICS common stock. He exercised a stock option for 4,910 shares, then sold 4,910 shares of common stock the same day, ending with 12,670 directly owned shares.

How many UNITED THERAPEUTICS (UTHR) shares did Ray Kurzweil sell?

Ray Kurzweil sold 4,910 shares of UNITED THERAPEUTICS common stock. The Form 4 states these shares were sold at a price per share of 489.0200, and his direct common stock holdings afterward totaled 12,670 shares.

Did Ray Kurzweil exercise stock options in UNITED THERAPEUTICS (UTHR)?

Yes. Ray Kurzweil exercised a stock option for 4,910 shares of UNITED THERAPEUTICS on March 4, 2026. This option exercise led to acquiring 4,910 shares of common stock at a stated price per share of 101.8000 before any subsequent sale.

What is Ray Kurzweil’s direct share ownership in UNITED THERAPEUTICS after these transactions?

Following the reported option exercise and sale, Ray Kurzweil directly owned 12,670 shares of UNITED THERAPEUTICS common stock. This total reflects his holdings after exercising a 4,910-share option and selling 4,910 shares on March 4, 2026.

What transaction codes were used in Ray Kurzweil’s UNITED THERAPEUTICS (UTHR) Form 4?

The Form 4 lists code M for the stock option exercise and related common stock acquisition, indicating an exercise or conversion of a derivative security, and code S for the open-market sale of 4,910 shares of common stock.